CD274 and breast carcinoma: However, given the low recruitment of both T cells and NK cells as well as low tumor and immune cell expression of PD-L1 in HR+ breast cancer, it will be important to identify other ways to modulate the TME to successfully activate an anti-tumor immune response in HR+ breast cancer.